IsoTis Accell gains FDA clearance
This article was originally published in The Gray Sheet
Executive Summary
Integra LifeSciences' pending acquisition of orthobiologics firm IsoTis moves a step closer to completion with the Aug. 15 receipt of 510(k) clearance for IsoTis' Accell line of demineralized bone matrix products. Accell is a key asset of the $51 million deal, which was announced Aug. 7 and conditioned upon Accell market go-ahead. The Accell products are indicated for use as bone graft extenders in the spine, extremities and pelvis, or as bone void fillers in the extremities and pelvis (1"The Gray Sheet" Aug. 13, 2007, p. 10)...
You may also be interested in...
Integra Buys IsoTis, Gains Accell Demineralized Bone Matrix In $51 Mil. Deal
Closure of Integra LifeSciences' acquisition of orthobiologics firm IsoTis is conditioned upon 510(k) clearance for IsoTis' Accell line of demineralized bone matrix products, Integra says
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.